Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued weight loss. While well-tolerated, further long-term studies are needed to evaluate its safety and efficacy.

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early trial results.

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed pounds.

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself “at my ideal body weight,” with his cholesterol below 200 for the first time in 20 years.

The bloom may be off the rose for obesity drugs as reports of side effects for high doses of GLP-1 drugs. GLP-1s were originally designed to treat diabetes, but showed effectiveness in weigh loss. The space is currently dominated by Eli Lilly (NYSE:LLY),